title: [Antioxidants treatment of severe post-operative pyoinflammatory and septic complications].
abstract: New medical human lactoferrin product called Laprot possessing antioxidant, detoxicant, anti-inflammatory immunomodulating properties was developed and registered (serial number LS-002374) in the P.A. Hertsen Institute. System (intravenous) administration of Laprot is efficacious detoxicant and anti-inflammatory treatment in patients with severe postoperative pyoinflammatory and septic complications accompanied by polyorgan failure. Local administration contributes to clinically apparent cleansing of festering wounds and cavities, regress of local pyoinflammatory processes, reduction of local purulo-necrotic processes of trachea's mucosa. Laprot administrated intravenously as in the case of topical administration is well tolerated by the patients and doesn't cause any side affects.
authors.forename: V I
authors.initials: VI
authors.lastname: Chissov
authors.forename: R I
authors.initials: RI
authors.lastname: Iakubovskaia
authors.forename: E R
authors.initials: ER
authors.lastname: Nemtsova
authors.forename: N A
authors.initials: NA
authors.lastname: Osipova
authors.forename: N V
authors.initials: NV
authors.lastname: Edeleva
authors.forename: M M
authors.initials: MM
authors.lastname: Utkin
authors.forename: A A
authors.initials: AA
authors.lastname: Zviagin
mesh_terms: D000287:Administration, Topical; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D018805:Sepsis / Q000188:drug therapy*; D013530:Surgical Wound Infection / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants